ReviewCurrent urology reports2007
Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects.
Review in Current urology reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 22 citations in OpenAlex.
- Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis.Dementia & neuropsychologia · 2023Review
- An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents.BMC geriatrics · 2017Article
- Imidafenacin has no influence on learning in nucleus basalis of Meynert-lesioned rats.Naunyn-Schmiedeberg's archives of pharmacology · 2013Article
- Brain penetration of the OAB drug trospium chloride is not increased in aged mice.World journal of urology · 2013Article
- Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.Drugs & aging · 2012Review
- Anticholinergics for overactive bladder therapy: central nervous system effects.CNS neuroscience & therapeutics · 2012Review
- The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome.Journal of neurogastroenterology and motility · 2011Article
- Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.International urogynecology journal · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimuscarinic drugs commonly used to treat overactive bladder are often associated with central nervous system (CNS) side effects including cognitive dysfunction, memory impairment, dizziness, fatigue, and headache. New agents show reduced CNS penetrance and better selectivity for the M3 muscarinic receptor. However, changes associated with aging may lead to alterations in blood-brain barrier permeability. Therefore, use of antimuscarinics in the elderly or in patients with Alzheimer's disease presents a significant challenge. This review highlights muscarinic receptor distribution and function in the CNS, provides a description and incidence of CNS side effects with therapy, offers information specific to currently available agents, and describes the use of antimuscarinics in special populations including children, the elderly, and patients with Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.